Category Archives: Cancer News

Heat-related deaths may increase with climate change

Heat-related deaths in New York City's borough of Manhattan may rise about 20 percent over the next decade, according to a new study. Researchers at Columbia University in New York analyzed the relationship between daily temperatures and temperature-related deaths across all seasons between 1982 and 1999 in Manhattan, which comprises the most densely populated county in the United States. The findings were published online May 19 in the journal Nature Climate Change. Using projections from 16 global climate models, the scientists found that the number of heat-related deaths in the city could increase by 20 percent by the 2020s, and in some worst-case scenarios, could rise by 90 percent or more by the 2080s, said study co-author Patrick Kinney, an environmental scientist at the Mailman School of Public Health at Columbia University. [Top 10 Surprising Results of Global Warming] To make their estimates, Kinney and his colleagues used the 1980s as a baseline, during which about 370 Manhattan residents died yearly from overheating. With this figure as a reference, a 20 percent increase could mean 74 additional yearly heat-related fatalities in Manhattan by the 2020s. “What we found was that there could be some benefits, in terms of reduced fatalities in the wintertime because of warmer temperatures, but our analysis suggests that those benefits are outweighed by extra fatalities that will occur in the hotter times of the year,” Kinney said. Mercury rising Daily readings in Manhattan's Central Park demonstrate that average monthly temperatures have increased 3.6 degrees Fahrenheit (2 degrees Celsius) between 1901 and 2000. Last year was the warmest year on record in Manhattan, and projections predict rising temperatures over the next six decades, the researchers said. In 2011, 206 people died due to extreme heat in the United States. “The warming that's anticipated from climate change is happening throughout the year, so the months that are already hot like June, July and August are going to get hotter, but months that are more moderate, like May and September, may become uncomfortably hot or fatally hot,” Kinney explained. In their study, Kinney and his colleagues applied climate models to two scenarios: one that assumed rapid global population growth with limited efforts to control emissions, and another that assumed slower population growth combined with technological advances to decrease emissions by the year 2040. The researchers found that both projections pointed to increases in temperature-related fatalities. “It was a little surprising that no matter which climate model we used, and which scenario of greenhouse gases we used, they all consistently showed this effect of increasing fatality risk in the future,” Kinney said. More of the same And Manhattan is not alone, Kinney added. The trend toward more fatalities is also expected for other cities, particularly in the northern United States. “Climate models of future temperatures do vary a bit from place to place, but generally the story is pretty much the same,” Kinney said. The effects are not limited to cities, but heat waves are typically more severely felt in densely populated areas. This is because cities tend to concentrate heat, with buildings and pavement surfaces soaking up heat during the day and releasing it at night, the researchers said. “This serves as a reminder that heat events are one of the greatest hazards faced by urban populations around the globe,” study co-author Radley Horton, a climate scientist at Columbia University, said in a statement. The way of the future The researchers acknowledge uncertainties in their projections, including that heat's effects could be made better or worse with changing demographics, and how fatalities may be prevented with better infrastructure or public policies. Still, the findings suggest that cities and governments need to do more to address the potential dangers posed by heat waves, said Richard Keller, an associate professor of medical history and bioethics at the University of Wisconsin-Madison, who was not involved with the study. “We have needed to rethink the dangers of heat for years,” Keller said. “The Chicago heat wave of 1995, and especially the European heat wave of 2003 both caused catastrophic excess mortality.” Major federal programs provide heating assistance in the winter, but there is no concomitant program for cooling assistance in the summer, Keller said. Kinney said that to combat the effects of deadly heat waves, cities can open community cooling centers, plant trees or construct “green” roofs. The new findings demonstrate the importance of developing strategies to adapt to future higher temperatures. “Heat is a major and often underestimated killer,” Keller said. “While we evacuate in the face of hurricanes and floods, we tend to ignore extreme heat, with deadly consequences. The 2003 heat wave killed nearly 15,000 people in France alone eight times the mortality associated with Hurricane Katrina.” Copyright 2013 LiveScience, a TechMediaNetwork company. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.source : http://www.foxnews.com/health/2013/05/23/heat-related-deaths-in-nyc-may-increase-with-climate-change/

Researchers move closer to development of universal flu vaccine

Researchers say they have made a major step towards the development of a universal flu vaccine, after a new immunotherapy approach has shown promise in animal studies, Medical News Today reported. The method involves creating a stronger immune reaction against the flu virus in the body, protecting against more viral strains than the current vaccines do. A new flu vaccine is developed each year in order to offer the most protection against the circulating viruses.  But for the developers, it is usually a race against the clock, as the data they use quickly becomes out of date once it reaches them. Also, there is always the possibility that new flu virus strains will emerge after the vaccine has been created. The development of a universal flu vaccine would eliminate the need for the development of annual flu shots. To test their new approach, researchers from the National Institute of Allergy and Infectious Diseases (NIAID) created a vaccine that utilized a fusion of the protein ferritin, which can assemble itself into tiny nanoparticles, and the protein hemagglutinin (HA), which is found on the surface of the influenza virus.   The protein combination ultimately produced nanoparticles with eight protruding viral spikes, which served as the basis for the vaccine’s antigen – what the immune system responds to when creating antibodies. Through a series of tests on mice and ferrets, the researchers found the vaccine was more effective at boosting immunity against a much wider range of virus strains than the current flu vaccine, including strains they were not testing for. According to the researchers, the vaccine is effective because it prompts the immune system to develop antibodies to the parts of the flu virus that stay the same from strain to strain.  They say the study’s findings, published in the journal Nature, could lead to a universal flu vaccine that protects against numerous strains of the influenza virus. Click for more from Medical News Today.source : http://www.foxnews.com/health/2013/05/23/researchers-move-closer-to-development-universal-flu-vaccine/

Key find for early bladder cancer treatment

"With better knowledge of this protein, we can better determine a patient’s prognosis and see who needs more aggressive treatment immediately and who can be given a milder treatment without a risk to their life. We can see at an early stage which patients are in the risk zone for cancer recurrence," said Karolina Boman, a doctoral student at the Division of Pathology at Lund University…

Boosting body’s natural flu killers as way to offset virus mutation problem

Emergence of new influenza strains, such as the recent avian influenza (H5N1) and swine influenza (H1N1 2009), can lead to the emergence of severe pandemics that pose a major threat to the entire world population. Recently, the concern regarding the emergence of such a pandemic arose when a new and deadly avian influenza strain (H7N9) was discovered in China, causing the death of six people in only one month. The body’s immune system can fight influenza infection. Natural killer (NK) cells, which are an essential component of this system, can recognize and eliminate influenza-virus-infected cells and inhibit the spread of the virus in the respiratory system…

More doctors, hospitals using electronic records

The Obama administration says more doctors and hospitals are embracing technology as adoption of computerized medical records reaches a “tipping point” in America. A report Wednesday from Health and Human Services says more than 50 percent of doctors' offices and 4 in 5 hospitals have transitioned from paper to electronic records, thanks partly to more than $14 billion in government incentive payments. The hope is that electronic records will make caring for patients safer and less costly, by helping avoid mistakes and cutting down on duplication. But others say there's still a long way to go. An outside group's report last year found little progress in getting medical computers in different offices to talk to each other. Concerns have also surfaced about patient privacy and vulnerability to fraud.source : http://www.foxnews.com/health/2013/05/23/more-doctors-hospitals-using-electronic-records/

Pfizer takes its shot at a vaccine for evasive MRSA superbug

Kathrin Jansen is a microbiologist with at least two breakthrough vaccines to her name: she brought the cervical cancer vaccine Gardasil to market for Merck and helped develop the $4 billion a year pneumonia and meningitis vaccine Prevnar 13 for Pfizer. Jansen's next vaccine success could come by taming the superbug MRSA, a drug-resistant bacterium that she has seen ravage a healthy man up close and personally. Methicillin-resistant Staphylococcus aureus infects an estimated 53 million people globally and costs more than $20 billion a year to treat. In the United States alone, MRSA kills 20,000 Americans each year, exceeding annual deaths from AIDS. Jansen watched the infection unfold two years ago when visiting her stepfather, who was in the hospital for a hip replacement. The man in the bed next door died soon after MRSA attacked the vascular graft in his leg. “He went in healthy and died very quickly,” recalls Jansen, senior vice president of vaccine research and early development at Pfizer Inc, the world's largest drug maker. She says the experience steeled her resolve to develop an effective vaccine that could prevent such deaths. But Staphylococcus aureus has proven a tenacious adversary. In the past decade, vaccine candidates by Nabi Biopharmaceuticals and Merck & Co Inc failed in costly, late-stage clinical trials. Now, led by Jansen, Pfizer is taking a shot. Competitors, including vaccine giants GlaxoSmithKline, Novartis and Sanofi, are, too. And while the race could lead to a viable vaccine, potentially worth billions in sales, critics say companies may be risking costly failure with so much work on a bacterium that is still barely understood. 'Bag of trouble' Staph has been living in and on its human hosts for centuries. At any given time, 25 to 35 percent of individuals will test positive for staph, often with no symptoms. But the bacterium can cause a range of diseases from boils and impetigo to raging blood infections and deadly bacterial pneumonia. The discovery of penicillin in 1928 gave doctors a way to defeat staph infections, but overuse and misuse gave rise to drug-resistant staph. Methicillin was developed to overcome drug-resistance, but by the 1960s, staph evolved new defenses to overcome this more powerful version of penicillin. Thus began the decades-long battle against methicillin-resistant staph, now the most common cause of hospital-acquired infections that is increasingly spreading into army barracks, prisons and daycare centers. Dr. Bill Gruber, a Pfizer senior vice president who led clinical trials for Prevnar 13 and is running the company's Staph aureus trials, thinks of the bacterium as “a little bag of trouble.” “Basically, it has a number of different toxins and defenses to try to defeat you.” That may explain why vaccines from Nabi and Merck failed. Both tried to defeat this bug by attacking on just one front. The vaccine by Nabi, now Biota Pharmaceuticals, focused only on the sugar capsule the bacteria make to hide from the immune system, while Merck's focused on a single protein that helps staph gets its nutrition. Neither lived up to expectations. “We've learned that just focusing on one target of Staph aureus might not be sufficient,” said Dr. Buddy Creech, an infectious diseases expert at Vanderbilt University. It takes stamina Jansen has been working on a Staph aureus vaccine for the past decade, first at Merck, then at Wyeth, and now at Pfizer. The East German-born scientist - who fled to the West in 1960 and earned her PhD in biology at Philipps University in Marburg - says it takes stamina to develop a successful vaccine, a process that can take 15 years or more. With the cervical cancer vaccine Gardasil, which had 2012 sales of $1.6 billion, it took 14 years from lab bench to government approval. “That's actually a fast development program,” she said. With Staph aureus, it took eight years from the first experiments to human safety trials. Now, it could take another seven to 10 years to wind up clinical trials, putting the team about midway through the process. Pfizer's initial vaccine targeted three mechanisms key to staph's survival and ability to cause disease. Two of those focused on sugar capsules. The third attacks a mechanism called “clumping factor,” which allows bacteria to stick to proteins when they enter the body. But Jansen's team wanted one more point of attack. They added a fourth antigen, a protein that allows the bacterium to steal manganese - a key nutrient - from host cells. The result is a four-antigen vaccine that generates antibody responses at distinct points of the life cycle of the bug. The company is testing this in Phase 1/Phase 2 trials in healthy adults in the United States. If Pfizer gets the results they hope for, likely later this year, the company expects to meet with regulators to iron out a plan for larger trials involving thousands of individuals. Initially, the vaccine would be aimed at preventing infections in millions of people globally who need elective procedures such as a hip replacement. Ultimately, it could be used to protect people at risk in the broader community. Rival vaccines Pfizer is furthest along, but the large, untapped market, estimated to be worth $3 billion to $4 billion a year, has drawn interest from several companies. GlaxoSmithKline has been quiet about its approach. The drugmaker had been partnering with Nabi's failed StaphVax candidate, and in 2009 bought another Nabi candidate called PentaStaph for $46 million. Company researchers declined to discuss their program, but Glaxo spokeswoman Melinda Stubbee confirmed the company has a four-component vaccine in Phase 1 development. “We are still evaluating the data and haven't yet announced plans to present the data or to pursue further development,” she said. NovaDigm Therapeutics, a private company based in Grand Forks, North Dakota, is developing a single-antigen vaccine that targets both staph and yeast infections caused by the fungus Candida. Other rivals with early-stage programs include Novartis, which has a vaccine in Phase 1 trials, and Sanofi, which is partnering with privately held biotech Syntiron. Although academic researchers applaud these efforts, they say companies may be rushing into trials too soon, especially when so much is unknown about how staph interacts with people. “Our development of Staphylococcal vaccines has predated an adequate understanding of the human response to infection,” Creech said. For instance, it is still not clear whether a Staph aureus vaccine that protects against skin infections will also protect individuals from bloodstream infections. It may be that instead of preventing infection, some vaccines will merely blunt infection. Dr. Robert Daum, who leads the MRSA Research Center at the University of Chicago Medical Center, doubts any of the current candidates will make it into widespread use. “I am convinced we need a vaccine. I'm just not sure anyone knows how to make one yet.” Jansen, who knows Daum, said she understands his skepticism. “I'm a microbiologist. I know bacteria pretty well. They are very potent adversaries.” She says there's a reason the company was not the first out of the gate. “We wanted to make sure that we looked under all the rocks and found what we needed to find.” Tests in animals and people suggest the vaccine induces production of antibodies that defeat staph's defenses and kill the bacteria. “To our knowledge, we are the only ones who have demonstrated very, very robust killing responses.” That was enough for Jansen. “We essentially said, 'That's it. We put it together as best as we know how. Now is the time to test it.'”source : http://www.foxnews.com/health/2013/05/23/pfizer-takes-its-shot-at-vaccine-for-evasive-mrsa-superbug/

Sugary drinks tied to kidney stone risk

Adults who drink at least one sugar-sweetened drink a day are slightly more likely to develop kidney stones than people who rarely imbibe them, according to a new study. While the recommendation for kidney stone prevention has been to drink a lot of fluids, the study suggests that it's not just the amount of fluid but the type of drink that also matters. Dr. Gary Curhan, the senior author of the study, said patients often ask for dietary advice to help prevent kidney stones. While the recommendation has been to drink plenty of fluids, Curhan said, patients often ask, “what should I drink? There's a lot of lore out there.” To see whether the type of beverage might matter, Curhan, of the Channing Division of Network Medicine at Brigham and Women's Hospital, and his colleagues collected data from three massive surveys of nearly 200,000 people. The questionnaires surveyed participants every two to four years and asked about diet, lifestyle and health, including how much they drank certain beverages and whether they developed kidney stones. None of the people in the study had kidney stones at the start. They found that 159 out of every 100,000 people who drank a sugar-sweetened non-cola beverage, such as clear soda, less than once a week developed kidney stones, compared to 306 out of every 100,000 who drank soda daily. After accounting for other factors, that translated to a 33 percent greater chance of developing kidney stones. Frequent punch drinkers also had an 18 percent higher chance of developing kidney stones. For every 100,000 people who drank punch at least every day, 226 developed kidney stones, compared to 158 out of every 100,000 participants who had punch less than once a week. Curhan said that while the numbers of people developing kidney stones in each group are not enormously different, the increased risk spread across an entire population is quite big. “Sodas are so commonly used that even though the absolute rate doesn't look that different, if there's a huge number of people consuming it, then the magnitude on the public health can be quite substantial,” Curhan told Reuters Health. Other drinks, such as coffee, tea, wine, beer and orange juice were tied to a lower risk of developing kidney stones. For instance, 205 out of every 100,000 people who rarely drank coffee developed kidney stones, compared to 137 out of every 100,000 people who drank it daily. Just 96 out of every 100,000 people who drank red wine daily developed kidney stones, while 174 out of every 100,000 people who drank red wine less than once a week developed kidney stones. Curhan's study, published in the Clinical Journal of the American Society of Nephrology, follows others showing a link between stones and fructose, non-dairy calcium, vitamin C supplements and other factors. The new study doesn't prove cause-and-effect between certain drinks and kidney stones, but it's possible that sugar could be involved, Curhan said, because it might play a role in how the body handles calcium. Another possibility is that sugary drinks might be contributing to obesity, and obesity is also tied to a higher kidney stone risk, said Dr. Elaine Worcester, a professor at the University of Chicago, who was not part of the study. Despite the lack of proof of a cause-effect relationship, Worcester said “these kinds of studies are the best we have to give advice to our patients.”source : http://www.foxnews.com/health/2013/05/23/sugary-drinks-tied-to-kidney-stone-risk/

How to exercise without eating more

Maintaining that delicate balance of eating enough to fuel your workouts and not overdoing it afterwards is a source of confusion for even the most educated exerciser. Sometimes, those post-workout hunger pangs hit, begging you to replace what you just burned off. Other times, your brain is telling you it's time to reward your hard work (with extra cheese). Related: Foods That Will Make You Look Younger Recent research from Australia has reopened the debate on this quandary: Is it possible to exercise and not eat more? While findings have been mixed, a review of studies published in the journal Appetite showed that exercise does not, in fact, lead to a significant increase in calorie consumption. Related: Stylish Male Athletes Who Became Models And calories might not matter much anyway, according to Equinox tier 4 coach Dr. Paul Spector.  “The goal of someone who says they want to lose weight is really to lose fat and gain muscle,” Spector said. “Therefore the real question with regard to exercise and nutrition is how to maximize the use of fat as a fuel source. It's about body composition, not weight.” More: The Worst Celebrity Eyebrows of All Time Want to train your body to burn more fat?

Polish man gets face transplant just 3 weeks after injury

WARSAW, Poland – & A 33-year-old Polish man received a face transplant just three weeks after being disfigured in a workplace accident, in what his doctors said Wednesday is the fastest time frame to date for such an operation. It was Poland's first face transplant. Face transplants are extraordinarily complicated and relatively rare procedures that usually require extensive preparation of the recipient over a period of months or years. But medical officials said the Polish patient's condition was deteriorating so rapidly that a transplant was seen as the only way to save his life. The patient is now being watched for any potential infections. In a photo taken Tuesday, just six days after the surgery, the patient, identified only by his first name, Grzegorz, was shown giving a thumbs-up sign from his hospital bed. Another picture, based on computer tomography, showed the extensive damage to his skull. He was injured in an April 23 accident at his job at a stone mason's workshop near the southwestern city of Wroclaw when a machine used to cut stone tore off most of his face and crushed his upper jaw. He received intensive treatment at a hospital in Wroclaw that saved his life and eyesight. But an attempt to reattach his own face failed, leaving an area close to the brain exposed to infections, doctors said. The damage was too extensive for doctors to temporarily seal the exposed areas. So he was taken to the Cancer Center and Institute of Oncology in Gliwice, the only place in Poland licensed to perform face transplants. The center has experience in facial reconstruction for patients disfigured by cancer and its experts have practiced face transplants on cadavers. Doctors at the center said the 27-hour face and bone transplant was performed May 15 soon after a matching donor was found. The surgery reconstructed the area around the eyes, the nose, jaws and palate and other parts of the man's face. Pictures show stitches running from above the patient's right eye, under the left eye and around the face to the neck. The donor, a 34-year-old man, was chosen from a national registry of potential donors after his age, gender, blood group and body features were determined to be a good match for the injured man. The head of the team of surgeons and other specialists, Dr. Adam Maciejewski, said it was the first time a face transplant was carried out so soon after the damage. Face transplants are usually a last resort after conventional reconstructive and plastic surgeries have been tried. “In such an extensive injury, where the structures close to the skull base and in contact with the brain area are exposed, any infection would be dangerous, not to mention the impossibility to function normally, including problems with breathing, with eating,” Maciejewski said. “All that led us in one direction.” “We assume the surgery will allow the patient to return to normal life. He will be able to breathe, to eat, to see.” Maciejewski said that over time, the face will mold to the man's facial bone structure and he will not look like the donor. The patient is now breathing on his own and responds to questions by nodding his head or squeezing the hands of doctors. But his condition is serious and it will be months before the procedure can be declared a full success, said Dr. Krzysztof Olejnik, head of the team of anesthesiologists. Another member of the transplant team, surgeon Dr. Maciej Grajek, told The Associated Press that the patient was receiving drugs to ward off any potential viral, bacterial or skin infections, but the face is alive and is healing. Though he is in sterile isolation, the patient has started the rehabilitation process. He will stay on special drugs for the rest of his life to prevent rejection of his new face. More than two dozen transplants of the face or parts of the face have been performed around the world. The first one was a partial face transplant in a woman maimed by her dog in France in 2005. Dr. Bohdan Pomahac, who in 2011 led a team in the United States that performed a full face and double-hand transplant on a woman mauled by a chimpanzee, said in an email he believes that in the future surgeons will decide more swiftly on a transplant, just as the Polish team did. “This is the way we likely will practice in the future,” said Pomahac, a reconstructive surgeon at Harvard-affiliated Brigham and Women's Hospital in Boston. However, he cautioned that patients should be given more time to be fully involved in a decision that will have a life-long impact on them. “I still think that a traumatized patient, even with all the psychological support, probably has a hard time making the right decision within hours/days after life-changing trauma,” Pomahac said. Dr. Zbigniew Wlodarczyk, who has performed limb transplants in Poland but was not involved in the face transplant, told the AP the surgery was groundbreaking because it was carried out on a fresh injury and on tissues that have not healed, but that leaving such an extensive wound open would have led to infection and the patient's death. “Such rare but spectacular procedures show the possibilities of medicine today and advance it,” he said.  ”This places Poland in the elite group of countries performing such transplants.  source : http://www.foxnews.com/health/2013/05/23/polish-man-gets-face-transplant-just-3-weeks-after-injury/